Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Josep M. Llovet, Augusto Villanueva, Jorge A. Marrero, et al.
Hepatology (2020) Vol. 73, Iss. S1, pp. 158-191
Open Access | Times Cited: 320

Showing 1-25 of 320 citing articles:

Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 4382
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1150
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Amit G. Singal, Josep M. Llovet, Mark Yarchoan, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1922-1965
Open Access | Times Cited: 686
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma
Josep M. Llovet, Thierry de Baère, Laura Kulik, et al.
Nature Reviews Gastroenterology & Hepatology (2021) Vol. 18, Iss. 5, pp. 293-313
Closed Access | Times Cited: 676
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Chen Yang, Hailin Zhang, Linmeng Zhang, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 20, Iss. 4, pp. 203-222
Closed Access | Times Cited: 417
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, et al.
Nature Cancer (2022) Vol. 3, Iss. 4, pp. 386-401
Open Access | Times Cited: 272
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Shukui Qin, Minshan Chen, Ann‐Lii Cheng, et al.
The Lancet (2023) Vol. 402, Iss. 10415, pp. 1835-1847
Closed Access | Times Cited: 227
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 583-705
Open Access | Times Cited: 189
Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002–2020)
Philipp K. Haber, Marc Puigvehí, Florian Castet, et al.
Gastroenterology (2021) Vol. 161, Iss. 3, pp. 879-898
Open Access | Times Cited: 179
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial
QiJiong Li, Minke He, Huanwei Chen, et al.
Journal of Clinical Oncology (2021) Vol. 40, Iss. 2, pp. 150-160
Closed Access | Times Cited: 169
Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)
Hai‐Dong Zhu, Hai-Liang Li, Mingsheng Huang, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 155
Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Laura Torrens, Carla Montironi, Marc Puigvehí, et al.
Hepatology (2021) Vol. 74, Iss. 5, pp. 2652-2669
Open Access | Times Cited: 128
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma
Amit G. Singal, Yujin Hoshida, David J. Pinato, et al.
Gastroenterology (2021) Vol. 160, Iss. 7, pp. 2572-2584
Open Access | Times Cited: 124
90Y Radioembolization versus Drug-eluting Bead Chemoembolization for Unresectable Hepatocellular Carcinoma: Results from the TRACE Phase II Randomized Controlled Trial
Elisabeth Dhondt, Bieke Lambert, Laurens Hermie, et al.
Radiology (2022) Vol. 303, Iss. 3, pp. 699-710
Open Access | Times Cited: 113
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Mark Yarchoan, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 4, pp. 294-311
Closed Access | Times Cited: 93
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, et al.
Liver Cancer (2022) Vol. 11, Iss. 4, pp. 354-367
Open Access | Times Cited: 88
2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

Korean Journal of Radiology (2022) Vol. 23, Iss. 12, pp. 1126-1126
Open Access | Times Cited: 88
Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a single-centre, single-arm study
Edward Kim, Alex Sher, Ghadi Abboud, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 9, pp. 843-850
Closed Access | Times Cited: 84
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Journal of Liver Cancer (2022) Vol. 23, Iss. 1, pp. 1-120
Open Access | Times Cited: 80
Cancer‐associated fibroblast‐derived secreted phosphoprotein 1 contributes to resistance of hepatocellular carcinoma to sorafenib and lenvatinib
Jung Woo Eun, Jung Hwan Yoon, Hye Ri Ahn, et al.
Cancer Communications (2023) Vol. 43, Iss. 4, pp. 455-479
Open Access | Times Cited: 79
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment
Josep M. Llovet, Arndt Vogel, David C. Madoff, et al.
CardioVascular and Interventional Radiology (2022) Vol. 45, Iss. 4, pp. 405-412
Open Access | Times Cited: 73
Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A Multicenter Proof-Of-Concept Study
Masatoshi Kudo, Tomoko Aoki, Kazuomi Ueshima, et al.
Liver Cancer (2023) Vol. 12, Iss. 4, pp. 321-338
Open Access | Times Cited: 64
Real-world efficacy and safety of TACE plus camrelizumab and apatinib in patients with HCC (CHANCE2211): a propensity score matching study
Zhi‐Cheng Jin, Bin‐Yan Zhong, Jian-Jia Chen, et al.
European Radiology (2023) Vol. 33, Iss. 12, pp. 8669-8681
Open Access | Times Cited: 40
Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study
Bruno Sangro, Masatoshi Kudo, Joseph P. Erinjeri, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 216-232
Closed Access | Times Cited: 11
Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study
Masatoshi Kudo, Zhenggang Ren, Yabing Guo, et al.
The Lancet (2025) Vol. 405, Iss. 10474, pp. 203-215
Closed Access | Times Cited: 9
Page 1 - Next Page

Scroll to top